RADIUS GLOBAL INFRASTRUCTURE RADI 深 沪
已收盘 09-21 16:00:00 美东时间
15.00
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 15.00
- 总市值 14.96亿
- 52周最高 15.18
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.97
- 委 比 0.00%
- 总股本 9971.70万
- 历史最高 18.79
- 量 比 0
- 振 幅 0.00%
- 历史最低 6.57
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多无锡微研：与英伟达AI计算液冷产品直接供应商维谛技术深化合作
10月28日，据“无锡微研”微信公众号消息，2023年以来，无锡微研有限公司与维谛技术（VERTIV）开始接触并进行合作，成功进入其供应链体系。随着数据中心业务...
10-28 11:20
Radico Khaitan Receives Independent ESG Rating
The latest announcement is out from Radico Khaitan Limited ( ($IN:RADICO) ). Ra...
10-26 19:03
Government Shutdown Begins: Chuck Schumer, Bernie Sanders Slam Trump — Elizabeth Warren Warns, 'Your Health Care Premiums Could More Than Double'
Democrats warn of health care crisis and criticize Republican and Trump for government shutdown, prioritizing politics over protecting Americans' coverage.
10-01 13:55
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
Radiopharm Theranostics received a positive recommendation from the DSMC to advance 177Lu-RAD202 to the next dose level of 75mCi in the Phase 1 'HEAT' trial for HER2+ advanced solid tumors. The first cohort treated with 30mCi showed positive safety and pharmacokinetic data, supporting acceleration to the second cohort. The company aims to share data from the first two cohorts by end-2025. RAD202, a radiopharmaceutical targeting HER2 expression, h...
10-01 12:00
RADIANT LOGISTICS ACQUIRES 80% OWNERSHIP STAKE IN MEXICO-BASED WEPORT
Strengthens North America Platform and Positions for Further Growth RENTON, Wash., Sept. 2, 2025 /PRNewswire/ -- Radiant Logistics, Inc. (NYSE American: RLGT), a leading provider of technolo...
09-03 04:05
Music Broadcast Ltd. Faces High Court Order on Royalty Calculations
An announcement from Music Broadcast Ltd. ( ($IN:RADIOCITY) ) is now available....
08-27 02:03
Praxis Precision Medicines To Present 12 Epilepsy Pipeline Updates, Including RADIANT Results, At IEC 2025 In Lisbon
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its participation in the upcoming
08-26 04:02
Radico Khaitan to Engage with Investors in Upcoming Conferences
Radico Khaitan Limited ( ($IN:RADICO) ) just unveiled an update. Radico Khaitan...
08-17 17:03
Praxis Announces Positive Results from RADIANT Study
An update from Praxis Precision Medicines ( ($PRAX) ) is now available. On Augu...
08-04 21:18
Guardant Health Study Shows Blood Test Detects Immunotherapy Response Early Across Multiple Cancer Types; Guardant Reveal Identified Non-Responders Up To 5 Months Before Standard Methods, Supporting Faster, More Effective Treatment Decisions In Advanced Cancer Care.
The first readout from Guardant's research collaboration with the Parker Institute for Cancer Immunotherapy (PICI) shows Guardant Reveal detected responses to immunotherapy across multiple tumor types and identified
07-29 20:09
